BioPharma APAC

Contract Services Contract Manufacturing

Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies

Medeologix, a Taiwan MedTech CDMO company announces its successful acquisition of three premier medical device manufacturing companies to form an integrate...

November 29, 2022 | News

Charles River Announces Cell Therapy Manufacturing Capacity Expansion, Reinforcing Commitment to CDMO Clients

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its cell therapy contract development and manufacturing (C...

November 08, 2022 | News

Polyplus and ENcell sign MOU for gene therapy discovery and optimization projects in Korea

“ENCell is working to accelerate viral vector CMO business via a collaboration with Polyplus.”, said Dr. Jong Wook Chang, CEO of ENCell. &ldquo...

October 28, 2022 | News

New Fully Automated Vetter Warehouse Expands Storage and Boosts Logistical Infrastructure

Vetter, a globally leading contract development and manufacturing organization (CDMO), announced the commissioning of a new warehouse designed to help meet...

October 28, 2022 | News

CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth

New research from the CPHI Annual Report 2022 – launched during CPHI Frankfurt (1-3 November, 2022) – predicts that huge volumes of V...

October 28, 2022 | News

Samsung Biologics Reports Third Quarter 2022 Financial Results

Recorded consolidated revenue of KRW 873 billion in Q3'22 Recorded consolidated operating profit of KRW 324.7 billion in Q3'...

October 27, 2022 | News

WuXi Biologics Announces GMP Release of 48,000L Commercial Drug Substance Manufacturing Facility in Hebei, China

The facility's design incorporates environmental protection, energy conservation, emission reduction, and resource utilization – a reflection of WuXi...

October 26, 2022 | News

WuXi Biologics adds further capacity and capability for drug product fill & finish

WuXi Biologics to provide global customers with end-to-end integrated solutions for diversified modalities, including mRNA-LNP. WuXi Biologics ("WuXi Bio"...

October 24, 2022 | News

CPHI Annual Report predicts growth for biologics manufacturing and CMOs in 2023

CPHI Frankfurt Report predicts ‘biologics outsourcing to surge in 2023, as China’s innovation engine stalls’ Ahead of the world’s ...

October 21, 2022 | News

GenScript ProBio Signs MOU to Form Strategic Partnership with GeneCraft

GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and GeneCraft (Suk Chul Bae, CEO), a global research team led by Professor Suk Ch...

October 18, 2022 | News

Samsung Biologics obtains three global ISO certifications

Receives accreditation for information security management system, information security in cloud services, and anti-bribery management systems F...

October 14, 2022 | News

Samsung Biologics unlocks additional capacity for production at its newest Plant 4

Plant 4 commences GMP operations within just 23 months since groundbreaking, as planned Partial operations add fresh biomanufacturing capacity of 60,000...

October 12, 2022 | News

WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody

Within the partnership, Toregem BioPharma will have access to WuXi Biologics' integrated CMC services in cell line development, cell banking and testing se...

October 12, 2022 | News

Vetter drives its sustainability campaign forward

Repeat participation in Baden Wuerttemberg’s Sustainability Days Greater inclusion of employees due to involvement in various initiatives Awards ...

October 11, 2022 | News

Stay Connected